The experience of blood glucose monitoring in people with type 2 diabetes mellitus (T2DM).
HbA1c
blood glucose
diabetes education
monitoring
patient experience
type 2 diabetes
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
08
09
2021
received:
29
07
2021
accepted:
10
09
2021
pubmed:
19
12
2021
medline:
6
5
2022
entrez:
18
12
2021
Statut:
ppublish
Résumé
Finger prick blood glucose (BG) monitoring remains a mainstay of management in people with type 2 diabetes (T2DM) who take sulphonylurea (SU) drugs or insulin. We recently examined patient experience of BG monitoring in people with type 1 diabetes (T1DM). There has not been any recent comprehensive assessment of the performance of BG monitoring strips or the patient experience of BG strips in people with T2DM in the UK. An online self-reported questionnaire containing 44 questions, prepared following consultation with clinicians and patients, was circulated to people with T2DM. 186 responders provided completed responses (25.5% return rate). Fixed responses were coded numerically (eg not confident = 0 fairly confident = 1). Of responders, 84% were treated with insulin in addition to other agents. 75% reported having had an HbA1c check in the previous 6 months. For those with reported HbA1c ≥ 65 mmol/mol, a majority of people (70%) were concerned or really concerned about the shorter term consequences of running a high HbA1c This contrasted with those who did not know their recent HbA1c, of whom only 33% were concerned/really concerned and those with HbA1c <65 mmol/mol of whom 35% were concerned. Regarding BG monitoring/insulin adjustment, only 25% of responders reported having sufficient information with 13% believing that the accuracy and precision of their BG metre was being independently checked. Only 9% recalled discussing BG metre accuracy when their latest metre was provided and only 7% were aware of the International Standardisation Organisation (ISO) standards for BG metres. 77% did not recall discussing BG metre performance with a healthcare professional. The group surveyed comprised engaged people with T2DM but even within this group there was significant variation in (a) awareness of shorter term risks, (b) confidence in their ability to implement appropriate insulin dosage (c) awareness of the limitations of BG monitoring technology. There is clearly an area where changes in education/support would benefit many.
Sections du résumé
BACKGROUND
Finger prick blood glucose (BG) monitoring remains a mainstay of management in people with type 2 diabetes (T2DM) who take sulphonylurea (SU) drugs or insulin. We recently examined patient experience of BG monitoring in people with type 1 diabetes (T1DM). There has not been any recent comprehensive assessment of the performance of BG monitoring strips or the patient experience of BG strips in people with T2DM in the UK.
METHODS
An online self-reported questionnaire containing 44 questions, prepared following consultation with clinicians and patients, was circulated to people with T2DM. 186 responders provided completed responses (25.5% return rate). Fixed responses were coded numerically (eg not confident = 0 fairly confident = 1).
RESULTS
Of responders, 84% were treated with insulin in addition to other agents. 75% reported having had an HbA1c check in the previous 6 months. For those with reported HbA1c ≥ 65 mmol/mol, a majority of people (70%) were concerned or really concerned about the shorter term consequences of running a high HbA1c This contrasted with those who did not know their recent HbA1c, of whom only 33% were concerned/really concerned and those with HbA1c <65 mmol/mol of whom 35% were concerned. Regarding BG monitoring/insulin adjustment, only 25% of responders reported having sufficient information with 13% believing that the accuracy and precision of their BG metre was being independently checked. Only 9% recalled discussing BG metre accuracy when their latest metre was provided and only 7% were aware of the International Standardisation Organisation (ISO) standards for BG metres. 77% did not recall discussing BG metre performance with a healthcare professional.
CONCLUSION
The group surveyed comprised engaged people with T2DM but even within this group there was significant variation in (a) awareness of shorter term risks, (b) confidence in their ability to implement appropriate insulin dosage (c) awareness of the limitations of BG monitoring technology. There is clearly an area where changes in education/support would benefit many.
Identifiants
pubmed: 34921531
doi: 10.1002/edm2.302
pmc: PMC8917860
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Insulin
0
Insulin, Regular, Human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00302Informations de copyright
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Références
Diabetes Care. 2014 Oct;37(10):2731-7
pubmed: 25249670
Prim Care Diabetes. 2020 Feb;14(1):12-20
pubmed: 31543458
Health Qual Life Outcomes. 2017 Jul 18;15(1):146
pubmed: 28720133
J Pharm Health Care Sci. 2019 Jan 22;5:2
pubmed: 30693091
Health Technol Assess. 2009 Feb;13(15):iii-iv, ix-xi, 1-50
pubmed: 19254484
Diabetes Technol Ther. 2018 Sep;20(9):613-621
pubmed: 30095980
Diabetes Res Clin Pract. 2020 Dec;170:108479
pubmed: 33002551
Diabetes Obes Metab. 2018 Jan;20(1):185-194
pubmed: 28730750
Diabetes Care. 1988 Jul-Aug;11(7):579-85
pubmed: 3203575
Diabet Med. 2014 Jan;31(1):40-6
pubmed: 23819529
J Diabetes Sci Technol. 2021 Jan;15(1):76-81
pubmed: 32172590
J Clin Pathol. 2021 Oct 13;:
pubmed: 34645702
BMJ. 2012 Apr 26;344:e2333
pubmed: 22539172
J Diabetes Metab Disord. 2015 May 19;14:43
pubmed: 26137451
Int J Clin Pract. 2018 Dec;72(12):e13252
pubmed: 30168887
J Pak Med Assoc. 2015 Dec;65(12):1360-2
pubmed: 26627526
Diabet Med. 1999 Sep;16(9):716-30
pubmed: 10510947
Endocrinol Diabetes Metab. 2022 Mar;5(2):e00302
pubmed: 34921531
Diabet Med. 2006 Sep;23(9):944-54
pubmed: 16922700
Clin Chem. 2012 May;58(5):906-15
pubmed: 22344287